Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects.

Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ.

BMC Infect Dis. 2011 Sep 17;11:244. doi: 10.1186/1471-2334-11-244.

2.

Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.

Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM.

J Int AIDS Soc. 2012 Mar 12;15(1):13. doi: 10.1186/1758-2652-15-13.

3.

Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.

Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T.

AIDS. 2013 Mar 13;27(5):781-5. doi: 10.1097/QAD.0b013e32835c54b8.

PMID:
23169331
4.
5.

Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.

Dlamini J, Ledwaba L, Mokwena N, Mokhathi T, Orsega S, Tsoku M, Kowo H, Proschan M, Khabo P, Maja P, Hadigan C.

Antivir Ther. 2011;16(4):605-9. doi: 10.3851/IMP1790.

PMID:
21685549
6.

Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study.

Phan V, Thai S, Choun K, Lynen L, van Griensven J.

PLoS One. 2012;7(1):e30647. doi: 10.1371/journal.pone.0030647. Epub 2012 Jan 27.

7.

Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment.

Gérard Y, Viget N, Yazdanpanah Y, Ajana F, de La Tribonnière X, Bocket L, Deuffic-Burban S, Dos Santos A, Ballester L, Mouton Y.

Therapie. 2003 Mar-Apr;58(2):153-8.

PMID:
12942856
8.

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP.

J Int AIDS Soc. 2013 Nov 19;16:18794. doi: 10.7448/IAS.16.1.18794.

9.

Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.

Pahuja M, Grobler A, Glesby MJ, Karim F, Parker G, Gumede S, Naidoo K.

Antivir Ther. 2012;17(4):737-43. doi: 10.3851/IMP2087. Epub 2012 Mar 13.

10.

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.

Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L; Médecins Sans Frontieres.

AIDS. 2006 May 12;20(8):1163-9.

PMID:
16691068
11.

A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011.

Dube NM, Summers R, Tint KS, Mayayise G.

Pan Afr Med J. 2012;11:39. Epub 2012 Mar 7.

12.

A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.

Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7. doi: 10.1097/QAI.0b013e318251aedd.

13.

Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.

Castelnuovo B, Kiragga A, Kamya MR, Manabe Y.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):59-63. doi: 10.1097/QAI.0b013e3181f5bd03.

PMID:
20861741
14.

Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa.

Stead D, Osler M, Boulle A, Rebe K, Meintjes G.

Antivir Ther. 2008;13(7):937-43.

PMID:
19043928
15.

Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.

Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB.

Neurology. 2009 Jan 13;72(2):165-70. doi: 10.1212/01.wnl.0000339042.96109.86.

16.

Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.

Lactic Acidosis International Study Group.

AIDS. 2007 Nov 30;21(18):2455-64. Review.

PMID:
18025882
17.

Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).

Feeney ER, Chazallon C, O'Brien N, Meiffrédy V, Goodall RL, Aboulker JP, Cooper DA, Yeni P, Mallon PW; INITIO Trial International Co-ordinating Committee.

HIV Med. 2011 Nov;12(10):602-9. doi: 10.1111/j.1468-1293.2011.00934.x. Epub 2011 May 22.

18.

Stavudine-induced hyperlactatemia/lactic acidosis at a tertiary communicable diseases clinic in South Africa.

Hernández Pérez E, Dawood H.

J Int Assoc Physicians AIDS Care (Chic). 2010 Mar-Apr;9(2):109-12. doi: 10.1177/1545109710361536.

PMID:
20484736
19.

Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.

Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.

Int J STD AIDS. 2003 May;14(5):350-5.

PMID:
12803944
20.

Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy.

Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P, Funk MJ, Kaufman JS, Van Rie A, Macphail P.

Clin Infect Dis. 2009 Jun 1;48(11):1617-23. doi: 10.1086/598977.

Items per page

Supplemental Content

Write to the Help Desk